Be a part of our medical cannabis research study!


Key Research Findings
Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. (2011)
  • “Chronic non-cancer pain conditions included neuropathic pain, fibromyalgia, rheumatoid arthritis, and mixed chronic pain.”
  • “Overall the quality of trials was excellent. Fifteen of the eighteen trials that met the inclusion criteria demonstrated a significant analgesic effect of cannabinoid as compared with placebo and several reported significant improvements in sleep.”
  • “There were no serious adverse effects. Adverse effects most commonly reported were generally well tolerated, mild to moderate in severity and led to withdrawal from the studies in only a few cases.”
  • “Overall there is evidence that cannabinoids are safe and modestly effective in neuropathic pain with preliminary evidence of efficacy in fibromyalgia and rheumatoid arthritis.”
Cannabis Use in Patients with Fibromyalgia: Effect on Symptoms Relief and Health-Related Quality of Life (2011)
  • “This observational study provides information on the patterns of cannabis use for therapeutic purposes among a group of patients with FM. Most of them were middle-aged women that did not respond to current treatment and self-administered marijuana, devoid of medical advice.”
  • 28 people with fibromyalgia who were herbal cannabis users and 28 non-users, without differences in demographics and clinical variables, were compared. After two hours of cannabis use, there was a statistically significant reduction of pain and stiffness, enhancement of relaxation and an increase in somnolence and feeling of well-being (all P values < 0.001). 
Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. (2006)
  • Daily recorded pain of the people with fibromyalgia was significantly reduced over a three-month period.
Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey. (2009)
  • One case series of 172 participants reported from Germany included 32 people with fibromyalgia. On average, participants received delta 9-THC 7.5 mg over seven months.
  • “In our patient sample, THC treatment led to a significant reduction in pain intensity. Noteworthy, this effect could be observed when a mean daily dose of 7.5 mg THC was administered. This dosage shows high acceptance and efficacy.”
Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. (2016)